Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
06:00am, Monday, 27'th Oct 2025
DUBLIN , Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, Novem
DUBLIN--(BUSINESS WIRE)--Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of “Power in the Periphery,” a new disease education campaign for healthcare professionals (HCPs) to r
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
06:00am, Tuesday, 14'th Oct 2025
A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had signif
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
12:30pm, Thursday, 11'th Sep 2025
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
06:00am, Tuesday, 02'nd Sep 2025
DUBLIN , Sept. 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C.
Topline results anticipated in Q1 2026 and , if successful, planning for expedited NDA submission If approved, ampreloxetine could address a critical unmet need as the first therapy with the potent
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
01:36pm, Wednesday, 13'th Aug 2025
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript
06:52pm, Tuesday, 12'th Aug 2025
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf -
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
06:26pm, Tuesday, 12'th Aug 2025
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.13 per share a year ago.
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 12'th Aug 2025
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year 1 Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer Completed sale of
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
06:00am, Monday, 28'th Jul 2025
DUBLIN , July 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2025 financial results and provide a business update after market close on Tuesday, Augu
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Wednesday, 23'rd Jul 2025
DUBLIN , July 23, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30 at 12:00 pm ET (
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
10:05am, Wednesday, 16'th Jul 2025
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA
06:00am, Thursday, 26'th Jun 2025
YUPELRI approved by China's NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive fur
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
12:56pm, Tuesday, 03'rd Jun 2025
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
